{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:14:06Z","timestamp":1790730846530,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T00:00:00Z","timestamp":1522368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment for frontal fibrosing alopecia (<jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content>) is challenging, and its treatment regimen often mirrors other lymphocytic\u2010predominant cicatricial alopecia. 5\u2010alpha\u2010reductase inhibitor (5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content>) has been reported with some treatment success in severe cases of <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To carry out evidence\u2010based analysis of articles published on treatment efficacy and safety of 5\u2010alpha\u2010reductase inhibitor for the treatment of <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Articles published on the use of 5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content> to treat <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content> between 2005 and 2017 were reviewed, analysed and graded according to the American College of Physicians outcome study grading system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were two studies with moderate level of evidence that described the efficacy of 5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content> for the treatment of <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content>. 5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content> was commonly used as adjunctive therapy with positive results in recalcitrant disease. Mild to moderate hair regrowth was reported in one grade 2 and three lower grade (one grade 3 and two grade 4) studies. There is limited evidence on the safety aspects of this medication in most studies that were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>Database studies might not fully account for confounders and are subjected to variations in methodology and data collection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This review demonstrated that <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content> patients treated with 5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content> could achieve either disease stability or reduction in the rate of progression in selected cases. A well\u2010designed randomized, double\u2010blind, controlled study would strengthen the role of 5<jats:styled-content style=\"fixed-case\">ARI<\/jats:styled-content> as part of treatment armamentarium for <jats:styled-content style=\"fixed-case\">FFA<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14930","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T06:12:37Z","timestamp":1520662357000},"page":"1385-1390","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["5\u2010alpha\u2010reductase inhibitor treatment for frontal fibrosing alopecia: an evidence\u2010based treatment update"],"prefix":"10.1111","volume":"32","author":[{"given":"A.","family":"Murad","sequence":"first","affiliation":[{"name":"Department of Dermatology Mater Misericordiae University Hospital Dublin Ireland"},{"name":"Department of Dermatology The Cleveland Clinic Foundation Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bergfeld","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Cleveland Clinic Foundation Cleveland OH USA"},{"name":"Department of Dermatopathology The Cleveland Clinic Foundation Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.2.235"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03042.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-3-201008030-00010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14287"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.043"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.026"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01291.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.05.014"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2015.08.003"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02963.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12499"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000162"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7753.114709"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590701214463"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)04927-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2002.tb00200.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)57727-9"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.7.910"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1257-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000450617"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.038"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:15:51Z","timestamp":1694988951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,30]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/jdv.14930"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14930","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,30]]},"assertion":[{"value":"2017-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}